Drugs
Azacitidine
3 articles published between September 3, 2026 and November 16, 2026.
WHAT THE STUDY ACTUALLY SAYSIn a 74-patient phase 1/2 study, venetoclax-based therapy plus the FLT3 inhibitor quizartinib produced remissions in about half of older adults unfit for chemo, and more in the FLT3-mutated subgroup.
3 min read
THE DRUG DOCKETGilead's phase 3 trial in 539 patients was terminated after the CD47 antibody failed to improve remission or survival and caused more fatal adverse events than azacitidine alone.
3 min read
WHAT THE STUDY ACTUALLY SAYSIn the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.
3 min read
This page indexes this newspaper’s reporting on Azacitidine. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.